Key Equity Research Analysts at H.C. Wainwright Maintained their ‘Buy’ rating for Rigel (NASDAQ:RIGL) Shares Today. Their Target Given is $7.5000

June 27, 2018 - By Henry Gaston

Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) Logo

Investors sentiment decreased to 1.23 in 2018 Q1. Its down 0.83, from 2.06 in 2017Q4. It is negative, as 13 investors sold Rigel Pharmaceuticals, Inc. shares while 27 reduced holdings. 14 funds opened positions while 35 raised stakes. 126.59 million shares or 0.43% less from 127.13 million shares in 2017Q4 were reported.

Loring Wolcott Coolidge Fiduciary Advsrs Ltd Liability Partnership Ma has invested 0% in Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL). Sg Americas Ltd Llc accumulated 17,388 shares. Rhumbline Advisers has invested 0% of its portfolio in Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL). Ameritas Invest Partners Inc reported 12,610 shares or 0% of all its holdings. Principal Gru Inc invested in 20,381 shares. First Personal Fincl Services invested in 0% or 950 shares. Price T Rowe Associates Md holds 0% or 2.69M shares in its portfolio. Teacher Retirement Of Texas holds 0% or 30,868 shares in its portfolio. 810 are held by Daiwa Group Incorporated Inc. Highbridge Mngmt Lc accumulated 108,250 shares or 0.01% of the stock. Schwab Charles Investment Mgmt stated it has 0% in Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL). 65,483 are owned by Ubs Asset Americas. Goldman Sachs Grp Inc holds 0% or 510,130 shares in its portfolio. Renaissance Technology Ltd Llc invested in 0% or 689,926 shares. Morgan Stanley stated it has 701,435 shares.

Since April 20, 2018, it had 0 insider buys, and 1 sale for $20,550 activity.

Rigel (NASDAQ:RIGL) Rating Reaffirmed

They currently have a $7.5000 price target on Rigel (NASDAQ:RIGL). The target price by H.C. Wainwright would suggest a potential upside of 147.52 % from the company’s last close price. This has been revealed in analysts report on 26 June.

Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) Ratings Coverage

Among 5 analysts covering Rigel (NASDAQ:RIGL), 5 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Rigel has $10 highest and $500 lowest target. $7.88’s average target is 160.07% above currents $3.03 stock price. Rigel had 14 analyst reports since January 19, 2018 according to SRatingsIntel. The stock of Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) earned “Buy” rating by H.C. Wainwright on Wednesday, May 2. On Friday, February 2 the stock rating was maintained by H.C. Wainwright with “Buy”. The firm earned “Buy” rating on Tuesday, June 26 by H.C. Wainwright. The stock of Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) earned “Buy” rating by H.C. Wainwright on Wednesday, April 18. As per Wednesday, April 18, the company rating was maintained by BMO Capital Markets. Cantor Fitzgerald maintained Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) rating on Tuesday, April 17. Cantor Fitzgerald has “Buy” rating and $600 target. H.C. Wainwright maintained Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) rating on Wednesday, March 7. H.C. Wainwright has “Buy” rating and $7.0 target. The firm has “Buy” rating given on Friday, January 19 by H.C. Wainwright. As per Tuesday, April 3, the company rating was maintained by H.C. Wainwright. The stock of Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) earned “Buy” rating by Jefferies on Wednesday, April 4.

The stock decreased 1.62% or $0.05 during the last trading session, reaching $3.03. About 24,676 shares traded. Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) has risen 61.57% since June 27, 2017 and is uptrending. It has outperformed by 49.00% the S&P500.

Analysts await Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) to report earnings on August, 7. They expect $-0.16 earnings per share, 0.00 % or $0.00 from last year’s $-0.16 per share. After $-0.17 actual earnings per share reported by Rigel Pharmaceuticals, Inc. for the previous quarter, Wall Street now forecasts -5.88 % EPS growth.

Rigel Pharmaceuticals, Inc., a clinical-stage biotechnology company, engages in the discovery and development of drugs in the therapeutic areas of immunology, oncology, and immuno-oncology. The company has market cap of $495.65 million. The companyÂ’s clinical programs include fostamatinib, an oral spleen tyrosine kinase inhibitor, which has completed Phase III clinical program for immune thrombocytopenia purpura; and Phase II clinical study for autoimmune hemolytic anemia and IgA nephropathy. It currently has negative earnings. It is also developing two oncology product candidates, which are in Phase I and Phase II.

More news for Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) were recently published by:, which released: “Reader Inquiry: Is Rigel Pharmaceuticals Due For A Near Term Breakout?” on June 11, 2018.‘s article titled: “Rigel Pharma (RIGL) Commences Phase 1 Clinical Trial of R835” and published on June 26, 2018 is yet another important article.

Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.